Apellis Pharmaceuticals (APLS) PT Lowered to $31 at Cantor Fitzgerald

March 18, 2026 6:56 AM

Cantor Fitzgerald analyst Steven Seedhouse lowered the price target on Apellis Pharmaceuticals (NASDAQ: APLS) to $31.00 (from $35.00) while maintaining ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found